Skip to content
Screener

NeoGenomics NEO Common Stock

Common Stock at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
150M0.0%
Labcorp Holdings logo
Labcorp HoldingsLH
265M0.0%
Quest Diagnostics logo
Quest DiagnosticsDGX
$2M0.0%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
$11K-92.5%
Personalis, Inc. logo
Personalis, Inc.PSNL
$10K+11.1%
Guardant Health logo
Guardant HealthGH
$1K0.0%

Other financials

Income statement

See full
Revenue$201.7M+11.2%
Gross profit$91.9M+18.9%
Operating income-$9.8M+79.5%
Net income$2.2M+105%
EPS (diluted)$0.02+106%

Balance sheet

See full
Cash & equivalents$145.5M-5.9%
Total debt$448.4M+534%
Total equity$785.7M-8.0%
Total assets$1.4B-3.0%

Cash flow

See full
Operating cash flow$20.0M-1.8%
CapEx$8.2M+30.0%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$2.13B+183%
Enterprise value$2.43B+264%
P/S2.8×+1.7×

Profitability

See full
Gross margin43.9%0.0pp
Operating margin-8.9%-2.8pp
Net margin-6.8%-2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-6.3%-2.0pp
Debt / equity0.6×+0.5×
Current ratio3.6×-0.3×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValueOutstanding.

The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001077183-26-000059
Line item(unaudited)June 30, 2026December 31, 2025
Total liabilities$566,511$523,268
Commitments and contingencies (Note 12)
Stockholders’ equity
Common stock, $0.001 par value, (250,000,000 shares authorized; 130,301,168 and 128,989,152 shares issued, respectively; 127,917,946 and 128,989,152 shares outstanding, respectively)$130$129
Treasury stock, at cost, (2,383,222 and 0 shares, respectively) (Note 7)(25,000)
Additional paid-in capital1,259,2721,270,235
Accumulated other comprehensive income44
Accumulated deficit(448,674)(433,806)

Item 1. Financial Statements (unaudited)

FAQ

What is NeoGenomics's common stock?
NeoGenomics (NEO) reported common stock of $130K in Q2 2026.
How has NeoGenomics's common stock changed year-over-year?
NeoGenomics's common stock increased by 1.6% year-over-year, from $128K to $130K.
What is the long-term trend for NeoGenomics's common stock?
Over 5 years (2020 to 2025), NeoGenomics's common stock has grown at a 2.9% compound annual growth rate (CAGR), from $112K to $129K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about NeoGenomics's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude